- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bioatla Inc (BCAB)
Bioatla Inc stock price live, this page displays NASDAQ BCAB stock exchange data. View the BCAB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Bioatla Inc real time stock price chart below.
What Is the Bioatla Inc Stock Price Today?
The Bioatla Inc stock price today is 3.320.
What Is the Stock Symbol for Bioatla Inc?
The stock ticker symbol for Bioatla Inc is BCAB.
Is BCAB the Same as $BCAB?
$BCAB is a common way to refer to the Bioatla Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Bioatla Inc Trade On?
Bioatla Inc is listed and trades on the NASDAQ stock exchange.
Is Bioatla Inc a Good Stock to Buy?
Determining whether Bioatla Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Bioatla Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCAB quote. (ISIN: US09077B2034)
What Is the Bioatla Inc Stock Price Today?
The Bioatla Inc stock price today is 3.320.
What Is the Stock Symbol for Bioatla Inc?
The stock ticker symbol for Bioatla Inc is BCAB.
Is BCAB the Same as $BCAB?
$BCAB is a common way to refer to the Bioatla Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Bioatla Inc Trade On?
Bioatla Inc is listed and trades on the NASDAQ stock exchange.
Is Bioatla Inc a Good Stock to Buy?
Determining whether Bioatla Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Bioatla Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCAB quote. (ISIN: US09077B2034)
3.320
+0.140(+4.40%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.033
3.400
52 wk Range
2.810
71.500
BCAB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.0333.400
52 wk Range
2.81071.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BCAB Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
10.000
Upside
+201.20%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Short term obligations exceed liquid assets
Form 8K Bioatla Inc For: 9 February- Investing.com
BioAtla explores sale as it cuts 70% of workforce- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 10.000
(+201.20% Upside)
Bioatla Inc SWOT Analysis
Strategic Crossroads | Discover BioAtla's strategic initiatives, including workforce reductions and partnership pursuits, aimed at extending its runway to key clinical milestones |
Pivotal Data Awaited | Learn about the critical upcoming ESMO conference, where BA3182 data could significantly impact BioAtla's future prospects and valuation |
Financial Tightrope | Delve into BioAtla's financial challenges, including rapid cash burn and elevated expenses, as it races to advance its promising oncology pipeline |
CAB Technology Edge | Explore BioAtla's innovative conditionally active biologics platform, aiming to revolutionize cancer treatment with enhanced efficacy and reduced side effects |
Bioatla Inc Earnings Call Summary for Q3/2025
- Bioatla reported Q3 2025 EPS of -$0.27, meeting forecasts, but stock fell 4.09% to $0.67 amid investor concerns over increased net losses of $15.8M and low cash reserves of $8.3M.
- Despite cost management efforts reducing R&D and G&A expenses, the company's net loss increased from $10.6M in Q3 2024, raising questions about financial sustainability.
- Bioatla achieved FDA alignment for a phase 3 trial in OPSCC, with CEO Jay Short announcing plans to begin enrollment early next year and key clinical readouts expected in H1 2026.
- Management plans to finalize a strategic transaction by year-end, focusing on prioritized programs while addressing the company's precarious cash position.
Last Updated: 11/13/2025, 05:22 PM
Read Full TranscriptEarnings
Latest Release
Aug 13, 2026
EPS / Forecast
0.27 / -0.17
Revenue / Forecast
6.5M / --
Compare BCAB to Peers and Sector
Metrics to compare | BCAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCABPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.2x | −1.7x | −0.3x | |
PEG Ratio | 0.00 | 0.08 | 0.00 | |
Price / Book | −0.2x | 1.8x | 2.6x | |
Price / LTM Sales | 0.7x | 17.2x | 3.1x | |
Upside (Analyst Target) | - | 226.5% | 47.6% | |
Fair Value Upside | Unlock | 12.4% | 5.6% | Unlock |
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Bioatla (BCAB) Stock Price Today?
The Bioatla stock price today is 3.320 USD.
What Stock Exchange Does Bioatla Trade On?
Bioatla is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Bioatla?
The stock symbol for Bioatla is "BCAB."
What Is the Bioatla Market Cap?
As of today, Bioatla market cap is 5.530M USD.
What Is Bioatla's Earnings Per Share (TTM)?
The Bioatla EPS (TTM) is -22.739.
When Is the Next Bioatla Earnings Date?
Bioatla will release its next earnings report on May 13, 2026.
From a Technical Analysis Perspective, Is BCAB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Bioatla Stock Split?
Bioatla has split 1 times.
How Many Employees Does Bioatla Have?
Bioatla has 41 employees.
What is the current trading status of Bioatla (BCAB)?
As of Aug 21, 2026, Bioatla (BCAB) is trading at a price of 3.320 USD, with a previous close of 3.180 USD. The stock has fluctuated within a day range of 3.033 USD to 3.400 USD, while its 52-week range spans from 2.810 USD to 71.500 USD.
What Is Bioatla (BCAB) Price Target According to Analysts?
The average 12-month price target for Bioatla is 10.000 USD, with a high estimate of 10 USD and a low estimate of 10 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +201.20% Upside potential.
What Is the BCAB Premarket Price?
BCAB's last pre-market stock price is 3.270 USD. The pre-market share volume is 1,570.000, and the stock has decreased by 0.090, or 2.830%.
What Is the BCAB After Hours Price?
BCAB's last after hours stock price is 3.150 USD, the stock has decreased by -0.030, or -0.940%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.